Management of heparin-induced thrombocytopenia: systematic reviews and meta-analyses

Martel, 2005, Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis, Blood, 106, 2710, 10.1182/blood-2005-04-1546 Smythe, 2007, The incidence of recognized heparin-induced thrombocytopenia in a large, tertiary care teaching hospital, Chest, 131, 1644, 10.1378/chest.06-2109 Warkentin, 2000, Impact of the patient population on the risk for heparin-induced thrombocytopenia, Blood, 96, 1703, 10.1182/blood.V96.5.1703 Nand, 1997, Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution, Am J Hematol, 56, 12, 10.1002/(SICI)1096-8652(199709)56:1<12::AID-AJH3>3.0.CO;2-5 Greinacher, 2005, Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis. A retrospective analysis of 408 patients, Thromb Haemost, 94, 132 Warkentin, 1996, A 14-year study of heparin-induced thrombocytopenia, Am J Med, 101, 502, 10.1016/S0002-9343(96)00258-6 Slattery, 2016, Thrombotics and Antithrombotics. Emergengy Medicine: A Comprehensive Study Guide, 8th ed., 1524 Cuker, 2016, Management of the multiple phases of heparin-induced thrombocytopenia, Thromb Haemost, 116, 835 Cuker, 2018, American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia, Blood Adv, 2, 3360, 10.1182/bloodadvances.2018024489 Wiercioch, 2020, Methodology for the American Society of Hematology VTE guidelines: current best practice, innovations, and experiences, Blood Adv, 4, 2351, 10.1182/bloodadvances.2020001768 Higgins Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, PLoS Med, 6, e1000097, 10.1371/journal.pmed.1000097 Whiting, 2016, ROBIS: A new tool to assess risk of bias in systematic reviews was developed, J Clin Epidemiol, 69, 225, 10.1016/j.jclinepi.2015.06.005 Higgins, 2011, Cochrane Handbook for Systematic Reviews of Interventions Sterne, 2016, ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions, BMJ, 355, i4919, 10.1136/bmj.i4919 Guyatt, 2008, GRADE: an emerging consensus on rating quality of evidence and strength of recommendations, BMJ, 336, 924, 10.1136/bmj.39489.470347.AD Chong, 2001, Prospective randomised open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopaenia with thrombosis: a clinical outcome study, Thromb Haemost, 86, 1170, 10.1055/s-0037-1616046 Kang, 2015, Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study, Blood, 125, 924, 10.1182/blood-2014-09-599498 Magnani, 2006, Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004, Thromb Haemost, 95, 967, 10.1160/TH05-07-0489 Lewis, 2001, Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia, Circulation, 103, 1838, 10.1161/01.CIR.103.14.1838 Lewis, 2003, Argatroban anticoagulation in patients with heparin-induced thrombocytopenia, Arch Intern Med, 163, 1849, 10.1001/archinte.163.15.1849 Al-Eidan, 2018, Comparison of argatroban and fondaparinux for the management of patients with isolated heparin-induced thrombocytopenia, Ann Hematol, 97, 2055, 10.1007/s00277-018-3422-6 Joseph, 2014, Bivalirudin for the treatment of patients with confirmed or suspected heparin-induced thrombocytopenia, J Thromb Haemost, 12, 1044, 10.1111/jth.12592 Warkentin, 2011, Fondaparinux treatment of acute heparin-induced thrombocytopenia confirmed by the serotonin-release assay: a 30-month, 16-patient case series, J Thromb Haemost, 9, 2389, 10.1111/j.1538-7836.2011.04487.x Srinivasan, 2004, Warfarin-induced skin necrosis and venous limb gangrene in the setting of heparin-induced thrombocytopenia, Arch Intern Med, 164, 66, 10.1001/archinte.164.1.66 Warkentin, 1997, The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia, Ann Intern Med, 127, 804, 10.7326/0003-4819-127-9-199711010-00005 Warkentin, 2017, Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review, Blood, 130, 1104, 10.1182/blood-2017-04-778993 Bethea, 2017, Treatment of pulmonary embolism with argatroban and ultrasound-assisted catheter-directed thrombolysis with alteplase in a patient with heparin-induced thrombocytopenia, Am J Health Syst Pharm, 74, 1153, 10.2146/ajhp160368 Davis, 2017, Direct acting oral anticoagulants for the treatment of suspected heparin-induced thrombocytopenia, Eur J Haematol, 99, 332, 10.1111/ejh.12921 Ezekwudo, 2017, Apixaban for treatment of confirmed heparin-induced thrombocytopenia: a case report and review of literature, Exp Hematol Oncol, 6, 21, 10.1186/s40164-017-0080-7 Samoš, 2019, Apixaban: a novel agent to treat heparin induced thrombocytopenia and to prevent embolism in patient with atrial fibrillation after multiple valve replacement?, J Thromb Thrombolysis, 48, 619, 10.1007/s11239-019-01910-0 Vavlukis, 2017, Can rivaroxaban be a drug of choice for treating heparin-induced thrombocytopenia in a patient with pulmonary thromboembolism?, Anatol J Cardiol, 18, 77 Farner, 2001, A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia, Thromb Haemost, 85, 950, 10.1055/s-0037-1615946 Schindewolf, 2012, Application, tolerance and safety of fondaparinux therapy in a German hospital: a prospective single-centre experience, Thromb Res, 129, 17, 10.1016/j.thromres.2011.06.008 Greinacher, 1999, Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators, Circulation, 100, 587, 10.1161/01.CIR.100.6.587 Jung, 2011, Risks of IVC filters in the setting of heparin-induced thrombocytopenia, J Thromb Haemost, 9, 334 Goel, 2015, Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality, Blood, 125, 1470, 10.1182/blood-2014-10-605493 Hopkins, 2008, Platelet transfusions in heparin-induced thrombocytopenia: a report of four cases and review of the literature, Transfusion, 48, 2128, 10.1111/j.1537-2995.2008.01822.x Refaai, 2010, Outcomes after platelet transfusion in patients with heparin-induced thrombocytopenia, J Thromb Haemost, 8, 1419, 10.1111/j.1538-7836.2010.03861.x Senzel, 2016, Negative heparin-induced thrombocytopenia test result after massive transfusion: believe it or not?, Am J Clin Pathol, 145, 717, 10.1093/ajcp/aqw031 Elalamy, 2009, Risk factors for unfavorable clinical outcome in patients with documented heparin-induced thrombocytopenia, Thromb Res, 124, 554, 10.1016/j.thromres.2009.04.002 Hong, 2003, Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia, Blood, 101, 3049, 10.1182/blood-2002-05-1448 Tardy, 1999, Lower limb veins should be systematically explored in patients with isolated heparin-induced thrombocytopenia, Thromb Haemost, 82, 1199, 10.1055/s-0037-1614355 Dyke, 2007, Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four/heparin antibodies, Ann Thorac Surg, 84, 836, 10.1016/j.athoracsur.2007.04.007 Koster, 2007, Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial, Ann Thorac Surg, 83, 572, 10.1016/j.athoracsur.2006.09.038 Czosnowski, 2008, Bivalirudin for patients with heparin-induced thrombocytopenia undergoing cardiovascular surgery, Ann Pharmacother, 42, 1304, 10.1345/aph.1K601 Koster, 2000, Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: a 1-year experience in 57 patients, J Cardiothorac Vasc Anesth, 14, 243, 10.1053/cr.2000.5861 Aouifi, 2001, Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia, Ann Thorac Surg, 71, 678, 10.1016/S0003-4975(00)02022-1 Furukawa, 2001, The use of argatroban as an anticoagulant for cardiopulmonary bypass in cardiac operations, J Thorac Cardiovasc Surg, 122, 1255, 10.1067/mtc.2001.116940 Fernandes, 2019, A 24-hour perioperative case study on argatroban use for left ventricle assist device insertion during cardiopulmonary bypass and veno-arterial extracorporeal membrane oxygenation, Perfusion, 34, 337, 10.1177/0267659118813043 Huang, 2014, Efficacy of therapeutic plasma exchange in heparin-induced thrombocytopenia patients prior to cardiac surgery with heparin, Transfusion., 54, 125A Jaben, 2011, Use of plasma exchange in patients with heparin-induced thrombocytopenia: a report of two cases and a review of the literature, J Clin Apher, 26, 219, 10.1002/jca.20289 Wadia, 2008, Intraoperative anticoagulation management during cardiac transplantation for a patient with heparin-induced thrombocytopenia and a left ventricular assist device, Tex Heart Inst J, 35, 62 Welsby, 2010, Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia, Anesth Analg, 110, 30, 10.1213/ANE.0b013e3181c3c1cd Palatianos, 2015, Perioperative use of iloprost in cardiac surgery patients diagnosed with heparin-induced thrombocytopenia-reactive antibodies or with true HIT (HIT-reactive antibodies plus thrombocytopenia): An 11-year experience, Am J Hematol, 90, 608, 10.1002/ajh.24017 Palatianos, 2004, Preoperative detection and management of immune heparin-induced thrombocytopenia in patients undergoing heart surgery with iloprost, J Thorac Cardiovasc Surg, 127, 548, 10.1016/j.jtcvs.2003.08.042 Makhoul, 1987, Management of patients with heparin-associated thrombocytopenia and thrombosis requiring cardiac surgery, Ann Thorac Surg, 43, 617, 10.1016/S0003-4975(10)60232-9 Koster, 2001, Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban, Anesthesiology, 94, 245, 10.1097/00000542-200102000-00013 Durand, 2008, Heparin-induced thrombocytopenia and cardiopulmonary bypass: anticoagulation with unfractionated heparin and the GPIIb/IIIa inhibitor tirofiban and successful use of rFVIIa for post-protamine bleeding due to persistent platelet blockade, Eur J Cardiothorac Surg, 34, 687, 10.1016/j.ejcts.2008.05.029 Koster, 2000, Cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia II and impaired renal function using heparin and the platelet GP IIb/IIIa inhibitor tirofiban as anticoagulant, Ann Thorac Surg, 70, 2160, 10.1016/S0003-4975(00)01888-9 Koster, 2001, One-year experience with the platelet glycoprotein IIb/IIIa antagonist tirofiban and heparin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II, J Thorac Cardiovasc Surg, 122, 1254, 10.1067/mtc.2001.118271 Olinger, 1984, Cardiopulmonary bypass for patients with previously documented heparin-induced platelet aggregation, J Thorac Cardiovasc Surg, 87, 673, 10.1016/S0022-5223(19)38447-8 Pötzsch, 2000, Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia, N Engl J Med, 343, 515, 10.1056/NEJM200008173430718 Selleng, 2008, Management of anticoagulation in patients with subacute heparin-induced thrombocytopenia scheduled for heart transplantation, Blood, 112, 4024, 10.1182/blood-2008-03-145243 Selleng, 2001, Emergency cardiopulmonary bypass in a bilaterally nephrectomized patient with a history of heparin-induced thrombocytopenia: successful reexposure to heparin, Ann Thorac Surg, 71, 1041, 10.1016/S0003-4975(00)02430-9 Warkentin, 2014, Serological investigation of patients with a previous history of heparin-induced thrombocytopenia who are reexposed to heparin, Blood, 123, 2485, 10.1182/blood-2013-10-533083 Warkentin, 2001, Temporal aspects of heparin-induced thrombocytopenia, N Engl J Med, 344, 1286, 10.1056/NEJM200104263441704 Davis, 2003, Favorable outcome with bivalirudin anticoagulation during cardiopulmonary bypass, Ann Thorac Surg, 75, 264, 10.1016/S0003-4975(02)04299-6 Grocott, 1997, Coagulation complicating cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia receiving the heparinoid, danaparoid sodium, J Cardiothorac Vasc Anesth, 11, 875, 10.1016/S1053-0770(97)90124-5 Kappa, 1987, Carotid endarterectomy in patients with heparin-induced platelet activation: comparative efficacy of aspirin and iloprost (ZK36374), J Vasc Surg, 5, 693, 10.1016/0741-5214(87)90156-X Nuttall, 2003, Patients with a history of type II heparin-induced thrombocytopenia with thrombosis requiring cardiac surgery with cardiopulmonary bypass: a prospective observational case series, Anesth Analg, 96, 344, 10.1213/00000539-200302000-00009 Warkentin, 2015, Plasma exchange to remove HIT antibodies: dissociation between enzyme-immunoassay and platelet activation test reactivities, Blood, 125, 195, 10.1182/blood-2014-07-590844 Lewis, 2002, Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia, Catheter Cardiovasc Interv, 57, 177, 10.1002/ccd.10276 Mahaffey, 2003, The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results, J Invasive Cardiol, 15, 611 Hale, 1998, Orgaran during rotational atherectomy in the setting of heparin-induced thrombocytopenia, Cathet Cardiovasc Diagn, 45, 318, 10.1002/(SICI)1097-0304(199811)45:3<318::AID-CCD23>3.0.CO;2-2 Lee, 2011, Comparison of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing an invasive strategy: a meta-analysis of randomized clinical trials, Int J Cardiol, 152, 369, 10.1016/j.ijcard.2010.08.007 Alatri, 2010, Treatment with argatroban in one haemodialysed patient with a heparin-induced thrombocytopenia and thrombotic complications, Intern Emerg Med, 5, 359, 10.1007/s11739-010-0357-x Athar, 2008, Prolonged half-life of argatroban in patients with renal dysfunction and antiphospholipid antibody syndrome being treated for heparin-induced thrombocytopenia, Am J Hematol, 83, 245, 10.1002/ajh.21072 Barginear, 2008, Heparin-induced thrombocytopenia complicating hemodialysis, Clin Appl Thromb Hemost, 14, 105, 10.1177/1076029607304405 Koide, 1995, Anticoagulation for heparin-induced thrombocytopenia with spontaneous platelet aggregation in a patient requiring haemodialysis, Nephrol Dial Transplant, 10, 2137 Link, 2009, Argatroban for anticoagulation in continuous renal replacement therapy, Crit Care Med, 37, 105, 10.1097/CCM.0b013e3181932394 Matsuo, 1988, Effect of synthetic thrombin inhibitor (MD805) as an alternative drug on heparin induced thrombocytopenia during hemodialysis, Thromb Res, 52, 165, 10.1016/0049-3848(88)90095-3 Matsuo, 1992, Treatment of heparin-induced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor, Br J Haematol, 82, 627, 10.1111/j.1365-2141.1992.tb06482.x Reddy, 2005, Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy, Ann Pharmacother, 39, 1601, 10.1345/aph.1G033 Williamson, 2004, Argatroban dosing in intensive care patients with acute renal failure and liver dysfunction, Pharmacotherapy, 24, 409, 10.1592/phco.24.4.409.33168 Yamamoto, 1996, Heparin-induced thrombocytopenia in hemodialysis patients, Am J Kidney Dis, 28, 82, 10.1016/S0272-6386(96)90134-1 Kommalapati, 2018, Upper limb phlegmasia cerulea dolens secondary to heparin-induced thrombocytopenia leading to gangrene, Cureus, 10, e2853 Trujillo Agudelo, 2018, Successful treatment of heparin-induced thrombocytopenia with apixaban in a patient with chronic kidney disease requiring hemodialysis, Clin Case Rep, 6, 2147, 10.1002/ccr3.1817 Al-Ali, 2016, Successful use of a bivalirudin treatment protocol to prevent extracorporeal thrombosis in ambulatory hemodialysis patients with heparin-induced thrombocytopenia, Hemodial Int, 20, 204, 10.1111/hdi.12379 de Pont, 2007, Pharmacokinetics and pharmacodynamics of danaparoid during continuous venovenous hemofiltration: a pilot study, Crit Care, 11, R102, 10.1186/cc6119 Lindhoff-Last, 2001, Use of a low-molecular-weight heparinoid (danaparoid sodium) for continuous renal replacement therapy in intensive care patients, Clin Appl Thromb Hemost, 7, 300, 10.1177/107602960100700409 Magnani, 2010, A review of 122 published outcomes of danaparoid anticoagulation for intermittent haemodialysis, Thromb Res, 125, e171, 10.1016/j.thromres.2009.10.008 Brown, 2013, Chronic fondaparinux use in a hemodialysis patient with heparin-induced thrombocytopenia type II and extracorporeal circuit thrombosis-a case report and review of the literature, Hemodial Int, 17, 444, 10.1111/hdi.12003 Haase, 2005, Use of fondaparinux (ARIXTRA) in a dialysis patient with symptomatic heparin-induced thrombocytopaenia type II, Nephrol Dial Transplant, 20, 444, 10.1093/ndt/gfh544 Zerbi, 2015, Use of fondaparinux for extracorporeal circuit anticoagulation in patients with heparin-induced thrombocytopenia type II (HIT II) on haemodiafiltration (HDF), Nephrol Dial Transplant, 30, iii236, 10.1093/ndt/gfv179.22 Ng, 2015, First experiences with the use of rivaroxaban in the treatment of heparin-induced thrombocytopenia, Thromb Res, 135, 205, 10.1016/j.thromres.2014.06.005 Liu, 2016, Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: a meta-analysis with trial sequential analysis of randomized controlled trials, Crit Care, 20, 144, 10.1186/s13054-016-1299-0